Press Releases on March 28, 2024 - EIN Presswire - Press Release Distribution Service

Published on March 28, 2024 - 20:05 GMT

Oxford: Owner of Tommy Bahama, Lilly Pulitzer and Johnny Was Reports Fourth-Quarter and Full-Year Fiscal 2023 Results; Posts 11% ...

Full-year sales increased 11% to $1.57 billion Fiscal 2023 GAAP EPS of $3.82 impacted by noncash impairment charges of $5.32 per share. Adjusted EPS of $10.15, within guidance range Initiates fiscal 2024 guidance of revenues of $1.630 billion to $1.670 …

Distribution channels:

Published on March 28, 2024 - 20:05 GMT

Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting ...

REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the company will deliver multiple …

Distribution channels: Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry ...

Published on March 28, 2024 - 20:05 GMT

Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights

Record consolidated net revenue of $84.5 million for full-year 2023 Fortress may receive up to four regulatory decisions on NDAs and BLAs in the next 18 months FDA accepted New Drug Application filing for DFD-29 to treat inflammatory lesions and erythema …

Distribution channels:

Published on March 28, 2024 - 20:05 GMT

TPI Composites, Inc. Publishes its Annual Sustainability Report Reaffirming Its Commitments to a Zero-Harm Culture and Carbon ...

SCOTTSDALE, Ariz., March 28, 2024 (GLOBE NEWSWIRE) -- TPI Composites, Inc. (Nasdaq: TPIC), today published its 2023 sustainability report highlighting its progress on organizational and global impacts related to sustainability. Bill Siwek, President, and …

Distribution channels: Consumer Goods ...

Published on March 28, 2024 - 20:05 GMT

ASML cautions investors regarding Tutanota LLC’s “mini-tender” offer

ASML cautions investors regarding Tutanota LLC’s “mini-tender” offer VELDHOVEN, the Netherlands, March 28, 2024 – ASML Holding NV (ASML) today announced that it recently became aware of an unsolicited “mini-tender” offer by Tutanota LLC to purchase up to …

Distribution channels: Technology ...

Published on March 28, 2024 - 20:05 GMT

Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights

Four candidates planned to be in clinical development in 2024 with interim data from two studies anticipated by year end Clinical development timelines accelerated for ABI-5366; now anticipating interim data from Phase 1a available in 3Q2024, initiation of …

Distribution channels:

Published on March 28, 2024 - 20:05 GMT

Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion ...

BOULDER, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on March 28, 2024 - 20:05 GMT

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

Announced Phase 2a study of SLS009 in r/r AML Showing 50% Response Rate in the Selected Optimal Dose of 30 mg BIW Exceeding the Targeted 20% and 100% Response Rate in Patients with Identified Biomarkers - Completed Enrollment in Phase 3 REGAL Study of …

Distribution channels:

Published on March 28, 2024 - 20:05 GMT

TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

FORT WORTH, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film …

Distribution channels:

Published on March 28, 2024 - 20:05 GMT

Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

-- Company to host call at 4:30pm today -- NEWTOWN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach …

Distribution channels:

Published on March 28, 2024 - 20:05 GMT

Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock ...

GAITHERSBURG, Md., March 28, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced results from a special meeting …

Distribution channels: Technology ...

Published on March 28, 2024 - 20:05 GMT

Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results

SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, …

Distribution channels:

Published on March 28, 2024 - 20:05 GMT

Leading Proxy Advisory Firms Recommend ContextLogic Stockholders Vote “FOR” Pending Transaction with Qoo10

ISS, Glass Lewis and Egan-Jones Endorse Proposed Transaction Stockholders are Encouraged to Vote FOR the Value-Maximizing Transaction Before the Electronic Proxy Voting Deadline of 11:59 P.M. Eastern Time on Thursday, April 11, 2024 SAN FRANCISCO, March 28 …

Distribution channels: Consumer Goods ...

Published on March 28, 2024 - 20:05 GMT

Ardelyx, Inc. Reports Employment Inducement Grants

WALTHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on March 28, 2024 - 20:05 GMT

Acuity Brands Declares Quarterly Dividend

Atlanta, March 28, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Acuity Brands, Inc. (NYSE: AYI; "Company") today declared a quarterly dividend of 15 cents per share. The dividend is payable on May 1, 2024, to shareholders of record on April …

Distribution channels: Banking, Finance & Investment Industry, Building & Construction Industry ...

Published on March 28, 2024 - 20:05 GMT

ArriVent BioPharma Reports Full Year 2023 Financial Results

Company progresses the development of furmonertinib with a data readout planned for 2024 Furmonertinib granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration Completed $201 million initial public offering (“IPO”) in January 2024 …

Distribution channels:

Published on March 28, 2024 - 20:05 GMT

CGRA Announces Completion and Publication of 2023 Annual Disclosure

NEW YORK, NY, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- CGrowth Capital Inc. (OTC: CGRA) is a public holding company for alternative and undervalued assets. The company is sector and industry agnostic and currently consists of two divisions …

Distribution channels: Companies, Mining Industry ...

Published on March 28, 2024 - 20:05 GMT

Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update

Positive Business Momentum and Sales Pipeline Growth Following FDA 510(k) Clearance of Vivos’ Proprietary Oral Medical Devices to Treat Severe Obstructive Sleep Apnea Annual Operating Expenses Declined 27% Due to Success of Cost Cutting Initiatives …

Distribution channels:

Published on March 28, 2024 - 20:05 GMT

Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b ...

The first cohort of patients were treated with multiple injections of CAN-3110 in the ongoing phase 1b clinical trial. The serial procedures were well tolerated without observed dose-limiting toxicity. A second cohort is being planned for enrollment in the …

Distribution channels: Healthcare & Pharmaceuticals Industry, Technology ...

Published on March 28, 2024 - 20:05 GMT

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

ATLANTA, March 28, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic …

Distribution channels: